These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 38538316)

  • 1. Complex karyotype determined using conventional cytogenetic analysis is a poor prognostic factor in patients with multiple myeloma.
    Uryu H; Mishima Y; Ishihara Y; Shirouchi Y; Yamauchi N; Hirano M; Hirano K; Teramoto Y; Yoshida K; Maruyama D
    J Clin Exp Hematop; 2024; 64(1):10-20. PubMed ID: 38538316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical relevance of high-risk cytogenetic abnormalities and the second revision of the International Staging System (R2-ISS) in patients with multiple myeloma in clinical practice.
    Mizuguchi M; Okamoto Y; Yagi H; Kagawa K; Sekimoto E; Shibata H; Shigekiyo T; Ozaki S
    Int J Hematol; 2023 May; 117(5):718-728. PubMed ID: 36692689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chromosome 1q21 Aberrations Are Poor Prognostic Factors for Newly Diagnosed Multiple Myeloma Patients.
    Wang T; Geng C; Yang G; Zhou H; Zhang Z; Jian Y; Chen W
    J Clin Lab Anal; 2024 Sep; 38(17-18):e25072. PubMed ID: 39263925
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Adverse effects of double-hit combining ISS-Ⅲ stage and 1q gain or del (17p) on prognosis of patients with newly diagnosed multiple myeloma].
    Liu XL; Yang YP; Bai J; Yue TT; Yang PY; Zhang Y; Fan HQ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Nov; 40(11):912-917. PubMed ID: 31856439
    [No Abstract]   [Full Text] [Related]  

  • 5. Characteristics and clinical outcome of high-risk multiple myeloma patients in Korea (KMM 1805).
    Kim K; Kim JS; Yoon SS; Yoon DH; Eom HS; Lee JJ; Yim HW; Park M; Lee H; Min CK;
    Int J Hematol; 2022 Jul; 116(1):110-121. PubMed ID: 35543899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. At least two high-risk cytogenetic abnormalities indicate the inferior outcomes for newly diagnosed multiple myeloma patients: a real-world study in China.
    Shen M; Yang G; Li X; Geng C; Huang Z; Chen W
    Leuk Lymphoma; 2021 Dec; 62(12):2992-3001. PubMed ID: 34219587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complex karyotype and translocation t(4;14) define patients with high-risk newly diagnosed multiple myeloma: results of CMG2002 trial.
    Nemec P; Zemanova Z; Kuglik P; Michalova K; Tajtlova J; Kaisarova P; Oltova A; Filkova H; Holzerova M; Balcarkova J; Jarosova M; Rabasova J; Hruba M; Spicka I; Gregora E; Adam Z; Scudla V; Maisnar V; Schutzova M; Hajek R;
    Leuk Lymphoma; 2012 May; 53(5):920-7. PubMed ID: 22023516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Influence of the number of high-risk cytogenetic abnormalities on the clinical characteristics and prognosis in 360 patients with newly diagnosed multiple myeloma].
    Chen Z; Xia Y; Guo R; Zhang R; Qiu HR; Jin YY; Li JY; Chen LJ
    Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):408-413. PubMed ID: 35680599
    [No Abstract]   [Full Text] [Related]  

  • 9. [Prognostic factors in newly diagnosed multiple myeloma patients with 1q21 amplification/gain treated with bortezomib-based regimens followed by autologous hematopoietic stem cell transplantation].
    Huang WY; Zou DH; Liu W; An G; Xu Y; Sui WW; Deng SH; Li CW; Liu H; Li J; Qiu LG
    Zhonghua Xue Ye Xue Za Zhi; 2018 Jun; 39(6):496-500. PubMed ID: 30032568
    [No Abstract]   [Full Text] [Related]  

  • 10. Chromosome 1 abnormalities and survival of patients with multiple myeloma in the era of novel agents.
    Giri S; Huntington SF; Wang R; Zeidan AM; Podoltsev N; Gore SD; Ma X; Gross CP; Davidoff AJ; Neparidze N
    Blood Adv; 2020 May; 4(10):2245-2253. PubMed ID: 32442299
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Characteristics and Prognostic Significance of Cytogenetic Abnormalities in Diffuse Large B-Cell Lymphoma Patients with Bone Marrow Involvement].
    Liu W; Lyu R; Huang WY; Li CW; Liu H; Li J; Zou DH; Qiu LG; Yi SH
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2017 Jun; 25(3):761-765. PubMed ID: 28641631
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Prognostic analysis of 182 newly diagnosed multiple myeloma patients with high risk cytogenetic abnormalities].
    Liu XL; Bai J; Fan HQ; Yang YP; Yue TT; Zhang Y; Yang PY; Gao SJ; Li W; Jin FY
    Zhonghua Xue Ye Xue Za Zhi; 2019 Aug; 40(8):644-649. PubMed ID: 31495130
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinical Utility of a Diagnostic Approach to Detect Genetic Abnormalities in Multiple Myeloma: A Single Institution Experience.
    Jung HA; Jang MA; Kim K; Kim SH
    Ann Lab Med; 2018 May; 38(3):196-203. PubMed ID: 29401553
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Cytogenetic abnormalities and prognosis of 532 patients with multiple myeloma].
    Wu H; Zhang H; He HY; Jiang H; Zhao YY; An R; He J; Li R; Lu J; Hou J
    Zhonghua Xue Ye Xue Za Zhi; 2017 Sep; 38(9):739-743. PubMed ID: 29081188
    [No Abstract]   [Full Text] [Related]  

  • 15. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy.
    Greenwell IB; Staton AD; Lee MJ; Switchenko JM; Saxe DF; Maly JJ; Blum KA; Grover NS; Mathews SP; Gordon MJ; Danilov AV; Epperla N; Fenske TS; Hamadani M; Park SI; Flowers CR; Cohen JB
    Cancer; 2018 Jun; 124(11):2306-2315. PubMed ID: 29579328
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amp 1q21 is more predictable with dismal survival than gain 1q21 of newly diagnosed multiple myeloma in real-world analysis.
    Wang YT; Bao L; Chu B; Chen XH; Lu MQ; Shi L; Gao S; Fang LJ; Xiang QQ; Ding YH
    J Clin Lab Anal; 2022 Jul; 36(7):e24375. PubMed ID: 35353920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and Prognostic Significance of High-Risk Cytogenetically Abnormalities in Multiple Myeloma Patients in Colombia.
    Combariza JF; Ordúz R; Agudelo C; Hernandez S; Madera AM; León G; Avila V; Bautista L; Valdés J; Camargo C; Sanchez V; Mejía F; Moreno L; Ramirez C
    Clin Lymphoma Myeloma Leuk; 2022 Aug; 22(8):601-607. PubMed ID: 35351414
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of cytogenetic abnormalities in T-cell prolymphocytic leukemia.
    Hu Z; Medeiros LJ; Fang L; Sun Y; Tang Z; Tang G; Sun T; Quesada AE; Hu S; Wang SA; Pei L; Lu X
    Am J Hematol; 2017 May; 92(5):441-447. PubMed ID: 28194886
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous Stem Cell Transplantation for Patients with Multiple Myeloma with Translocation (4;14): The MD Anderson Cancer Center Experience.
    Pasvolsky O; Gaballa MR; Milton DR; Masood A; Sami SS; Tanner MR; Bashir Q; Srour S; Saini N; Ramdial J; Nieto Y; Tang G; Lin P; Lee HC; Patel KK; Kebriaei P; Thomas SK; Weber DM; Orlowski RZ; Shpall EJ; Champlin RE; Qazilbash MH
    Transplant Cell Ther; 2023 Apr; 29(4):260.e1-260.e6. PubMed ID: 36646323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The t(11;14)(q13;q32) translocation as a poor prognostic parameter for autologous stem cell transplantation in myeloma patients with extramedullary plasmacytoma.
    Shin HJ; Kim K; Lee JJ; Song MK; Lee EY; Park SH; Kim SH; Jang MA; Kim SJ; Chung JS
    Clin Lymphoma Myeloma Leuk; 2015 Apr; 15(4):227-35. PubMed ID: 25812994
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.